|

99Tc-MDP Treatment for Knee Osteoarthritis

RECRUITINGN/ASponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Actively Recruiting
PhaseN/A
SponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Started2017-09-01
Est. completion2025-12-30
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02993029

Summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.

Eligibility

Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Participants with painful osteoarthritis;
2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan;
3. Participants voluntarily participate in the trial, and signed the informed consent.

Exclusion Criteria:

1. Knee joint replacement;
2. Inflammatory arthritis or joint infection of knee;
3. Nervous joint disease;
4. Fracture of joint;
5. Gout arthritis of the knee;
6. Traumatic arthritis.

Conditions2

ArthritisTreatment Outcome

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.